ArticleJournal of clinical microbiology2023
Plasma Microbial Cell-Free DNA Sequencing from over 15,000 Patients Identified a Broad Spectrum of Pathogens.
Article in Journal of clinical microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Pooled it
- The Utility of Microbial Cell-Free DNA in the Rapid Diagnosis of Chagas Disease: Chagas Disease Case Series.Open forum infectious diseases · 2026Article
- Article
- Microbial cell-free DNA for rapid pathogen identification in clinical diagnostics: a proof of concept study.Genome medicine · 2026Article
- Concurrent Burkholderia cepacia detected by plasma mcfDNA sequencing in a child with MRSA liver abscess and chronic granulomatous disease: a case report.BMC pediatrics · 2026Article
- Rapid Molecular Diagnostics for Bloodstream Infection in Patients with Chronic Kidney Disease.Diagnostics (Basel, Switzerland) · 2026Review
- Comparative study of plasma microbial cell-free DNA sequencing to culture and polymerase chain reaction in pediatric community-acquired pneumonia with parapneumonic effusion or empyema.Journal of clinical microbiology · 2026Article
- Mixed mycotic infection in an immunocompromised host with advanced HIV diagnosed with the assistance of a Karius test.Medical mycology case reports · 2026Article
- Article
- Fungal DNA in Circulation: A Sleuth's Clue to Predict Cardiovascular Risk for Hemodialysis Patients.Journal of the American Society of Nephrology : JASN · 2026Article
- Plasma microbial cell-free DNA sequencing for detection ofAntimicrobial stewardship & healthcare epidemiology : ASHE · 2026Article
- Diagnosis of histoplasmosis by next-generation sequencing of microbial cell-free DNA in Texas.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2026Article
- Refining the Clinical Utility of Plasma Microbial Cell-Free DNA Sequencing in High-Risk Population of Infection: A Narrative Review.Infection and drug resistance · 2026Review
- Clinical utility of plasma microbial cell-free DNA sequencing for early diagnosis of toxoplasmosis in high-risk patients: a five-patient case series.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2026Article
- Necrotizing pneumonia due to blastomycosis: Diagnostic challenges and the emerging role of cell-free DNA testing.IDCases · 2026Article
- Mindful diagnostics: a central nervous system infection case study.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2026Article
- Metagenomic next-generation sequencing reveals cross-reactivity of lateral flow cryptococcal antigen assay withASM case reports · 2026Article
- Pulmonary Nocardiosis Diagnosed by Plasma Metagenomic Next-Generation Sequencing in a Patient With Recurrent Febrile Neutropenia.Case reports in infectious diseases · 2026Article
- Bacterial cell-free DNA profiling reveals the co-elevation of multiple bacteria in newborn foals with suspected sepsis.iScience · 2025Article
- In-matrix library preparation for metagenomic sequencing of microbial cell-free DNA.Journal of clinical microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microbial cell-free DNA (mcfDNA) sequencing is an emerging infectious disease diagnostic tool which enables unbiased pathogen detection and quantification from plasma. The Karius Test, a commercial mcfDNA sequencing assay developed by and available since 2017 from Karius, Inc. (Redwood City, CA), detects and quantifies mcfDNA as molecules/μL in plasma. The commercial sample data and results for all tests conducted from April 2018 through mid-September 2021 were evaluated for laboratory quality metrics, reported pathogens, and data from test requisition forms. A total of 18,690 reports were generated from 15,165 patients in a hospital setting among 39 states and the District of Columbia. The median time from sample receipt to reported result was 26 h (interquartile range [IQR] 25 to 28), and 96% of samples had valid test results. Almost two-thirds (65%) of patients were adults, and 29% at the time of diagnostic testing had ICD-10 codes representing a diverse array of clinical scenarios. There were 10,752 (58%) reports that yielded at least one taxon for a total of 22,792 detections spanning 701 unique microbial taxa. The 50 most common taxa detected included 36 bacteria, 9 viruses, and 5 fungi. Opportunistic fungi (374 Aspergillus spp., 258 Pneumocystis jirovecii, 196
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.